These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2126536)

  • 21. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review.
    Petersein J; Saini S; Weissleder R
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):53-60. PubMed ID: 8673716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Focal nodular hyperplasia of the liver: imaging findings with emphasis on the findings of superparamagnetic iron oxide-enhanced MR imaging].
    Han JK; Kim SH
    Korean J Hepatol; 2006 Mar; 12(1):116-9. PubMed ID: 16565614
    [No Abstract]   [Full Text] [Related]  

  • 23. Splenic magnetic resonance imaging using particulate agents.
    Small WC; Nelson RC; Sherbourne GM; Bernardino ME
    Invest Radiol; 1994 Jun; 29 Suppl 2():S12-4. PubMed ID: 7928204
    [No Abstract]   [Full Text] [Related]  

  • 24. State of the art in diagnostic liver imaging.
    Lamprecht A; Wagner B
    Eur Radiol; 2004 Jan; 14 Suppl 1():C2-3. PubMed ID: 15113057
    [No Abstract]   [Full Text] [Related]  

  • 25. [Use of ultrasmall ferric oxide (Sinerem) particles as a magnetic resonance contrast substance for imaging lymph nodal metastases in cancer of the head and neck].
    Sviridov NK; Napolov IuK; Bolotova EN; Iakobs LV
    Vestn Rentgenol Radiol; 2004; (3):63-4. PubMed ID: 15587888
    [No Abstract]   [Full Text] [Related]  

  • 26. Experience with Resovist in gastroenterologic radiology and intervention.
    Vogl TJ; Schwarz W; Marquart F; Parmentier S; Götz B; Thalhammer A; Hammerstingl R
    Eur Radiol; 2004 Jan; 14 Suppl 1():C7-9. PubMed ID: 15113060
    [No Abstract]   [Full Text] [Related]  

  • 27. [Improved tumor diagnosis using MRI with organ-specific contrast media. Wiesbaden, 12 May 1999].
    Rofo; 1999 Jul; 171(1 Suppl):1-4. PubMed ID: 10467439
    [No Abstract]   [Full Text] [Related]  

  • 28. Hepatic in vivo video microscopic study for evaluating experimental and approved magnetic resonance contrast agents.
    Kruskal JB; Lunderquist A; Clouse ME
    Invest Radiol; 1994 Jun; 29 Suppl 2():S83-6. PubMed ID: 7928279
    [No Abstract]   [Full Text] [Related]  

  • 29. How can superparamagnetic iron oxides be used to monitor disease and treatment?
    Unger EC
    Radiology; 2003 Dec; 229(3):615-6. PubMed ID: 14657295
    [No Abstract]   [Full Text] [Related]  

  • 30. Iron oxides as MR imaging contrast agents.
    Fahlvik AK; Klaveness J; Stark DD
    J Magn Reson Imaging; 1993; 3(1):187-94. PubMed ID: 8428086
    [No Abstract]   [Full Text] [Related]  

  • 31. [The characterization value of feridex-enhanced MR imaging for focal hepatic lesions in reference to their histological pathology].
    Yang HF; Zhou XP; Yu JQ; Song B; Guang YS; Zhang HY; Chen X
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):548-50. PubMed ID: 16042902
    [No Abstract]   [Full Text] [Related]  

  • 32. The use of AMI-227 as an oral contrast agent for magnetic resonance imaging.
    Rogers J; Lewis J; Josephson L
    Invest Radiol; 1994 Jun; 29 Suppl 2():S81-2. PubMed ID: 7928278
    [No Abstract]   [Full Text] [Related]  

  • 33. Liver MR imaging with iron oxides: toward consensus and clinical practice.
    Weissleder R
    Radiology; 1994 Dec; 193(3):593-5. PubMed ID: 7972790
    [No Abstract]   [Full Text] [Related]  

  • 34. Imaging macrophage activity in the brain by using ultrasmall particles of iron oxide.
    Bulte JW; Frank JA
    AJNR Am J Neuroradiol; 2000 Oct; 21(9):1767-8. PubMed ID: 11039364
    [No Abstract]   [Full Text] [Related]  

  • 35. Important considerations in the design of iron oxide nanoparticles as contrast agents for TI-weighted MRI and MRA.
    Kellar KE; Fujii DK; Gunther WH; Briley-Saebø K; Bjornerod A; Spiller M; Koenig SH
    Acad Radiol; 2002 May; 9 Suppl 1():S34-7. PubMed ID: 12019889
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer.
    Kroon BK; Horenblas S
    J Urol; 2006 Mar; 175(3 Pt 1):1174. PubMed ID: 16469648
    [No Abstract]   [Full Text] [Related]  

  • 37. The potential value of iron oxide nanoparticles in brain tumor treatment.
    Gutin PH
    AJNR Am J Neuroradiol; 2002 Apr; 23(4):505. PubMed ID: 11950633
    [No Abstract]   [Full Text] [Related]  

  • 38. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
    De Gaspari A; De Cobelli F; Del Maschio A
    Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity of acute heart transplant rejection can be visualized by cellular and functional cardiac magnetic resonance.
    Epstein FH
    JACC Cardiovasc Imaging; 2009 Jun; 2(6):742-3. PubMed ID: 19520345
    [No Abstract]   [Full Text] [Related]  

  • 40. Water relaxation by SPM particles: neglecting the magnetic anisotropy? A caveat.
    Roch A; Muller RN; Gillis P
    J Magn Reson Imaging; 2001 Jul; 14(1):94-6. PubMed ID: 11436221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.